Zacks: Brokerages Expect Zogenix (ZGNX) Will Post Earnings of -$0.90 Per Share
Equities research analysts expect Zogenix (NASDAQ:ZGNX) to report ($0.90) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zogenix’s earnings. The highest EPS estimate is ($0.88) and the lowest is ($0.93). Zogenix also posted earnings of ($0.90) per share during the same quarter last year. The firm is scheduled to issue its next earnings results on Tuesday, August 14th.
On average, analysts expect that Zogenix will report full year earnings of ($3.89) per share for the current year, with EPS estimates ranging from ($4.61) to ($3.37). For the next financial year, analysts anticipate that the business will report earnings of ($2.35) per share, with EPS estimates ranging from ($3.69) to ($1.41). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Zogenix.
Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.13). During the same period last year, the company posted ($0.86) earnings per share.
Zogenix opened at $42.00 on Thursday, Marketbeat reports. Zogenix has a 12-month low of $10.05 and a 12-month high of $45.85.
In other Zogenix news, Director Roger Hawley sold 35,000 shares of Zogenix stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $44.71, for a total transaction of $1,564,850.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 5.00% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in Zogenix during the first quarter worth about $100,000. Meadow Creek Investment Management LLC bought a new position in Zogenix during the first quarter worth about $192,000. Neuburgh Advisers LLC bought a new position in Zogenix during the first quarter worth about $264,000. Tyers Asset Management LLC bought a new position in Zogenix during the first quarter worth about $337,000. Finally, WINTON GROUP Ltd bought a new position in Zogenix during the first quarter worth about $376,000. Hedge funds and other institutional investors own 99.36% of the company’s stock.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.